Why Novavax Could Beat Moderna in Europe After Pfizer's Huge EU Vaccine Deal

The name of the game with COVID-19 vaccines right now is supply deals. Companies with big supply agreements are in a position to make a lot of money.

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are arguably in the catbird's seat right now after securing a major supply deal with the European Union over the weekend. However, there could be another winner on the way as well.  Novavax (NASDAQ: NVAX) just might be set to beat Moderna (NASDAQ: MRNA) in Europe now that the EU inked a major contract with Pfizer and BioNTech.

Image source: Getty Images.

Continue reading

Source Fool.com